C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 16/46 (2006.01) A61K 31/7032 (2006.01) A61K 31/739 (2006.01) A61K 39/00 (2006.01) A61K 39/395 (2006.01) A61K 49/00 (2006.01) A61P 35/00 (2006.01) C07K 16/00 (2006.01) C07K 16/18 (2006.01) C07K 16/30 (2006.01) C07K 16/42 (2006.01) C12N 5/12 (2006.01) C12P 21/08 (2006.01)
Patent
CA 2441845
The invention relates to the obtention of genetically-engineered antibodies from the P3 (AcM P3) murine monoclonal antibody, which is produced by the hybridoma deposited under number ECACC 94113026 in accordance with the Budapest treaty, and from the 1E10 (AcMai 1E10) anti-idiotype thereof, which is produced by hybridoma ECACC 97112901, with the purpose of obtaining antibodies which have the same recognition properties as the originals but which are less immunogenic. The chimaeric antibodies contain the variable domains of murine immunoglobulin and the constant regions of human immunoglobulin. The humanised antibodies, in addition to containing the constant regions of human immunoglobulin, are modified in the murine frameworks (FRs) region and, in particular, in those areas that can be converted into a T-cell antigenic site, as a result of which some FRS positions are human. Said antibodies can be used for the diagnosis and therapy of different types of tumours.
La présente invention concerne l'obtention d'anticorps modifiés par génie génétique à partir de l'anticorps monoclonal murin P3 (AcM P3) produit par l'hybridome déposé selon le traité de Budapest sous le numéro ECACC 94113026, et de son anti-idiotype 1E10 (AcMai 1E10) produit par l'hybridome ECACC 97112901, dans le but d'obtenir des anticorps avec les mêmes propriétés de reconnaissance que les originaux mais moins immunogéniques que ceux-ci. Les anticorps chimériques contiennent les domaines variables de l'immunoglobuline murine et les régions constantes de l'immunoglobuline humaine. Les anticorps humanisés contiennent les régions constantes de l'immunoglobuline humaine et sont, de plus, modifiés dans la région des cadres (FRs) murins et, en particulier, dans les zones pouvant se convertir en un site antigénique pour les cellules T, certaines positions des FRS étant ainsi humaines. Ces anticorps peuvent être utilisés dans le diagnostic et la thérapie de différents types de tumeurs.
de Acosta Del Rio Cristina Maria Mateo
Lombardero Valladares Josefa
Lopez Requena Alejandro
Roque Navarro Lourdes Tatiana
Centro de Inmunologia Molecular
Macrae & Co.
LandOfFree
Ganglioside-associated recombinant antibodies and the use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ganglioside-associated recombinant antibodies and the use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ganglioside-associated recombinant antibodies and the use... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1712777